Allogene Therapeutics Inc...
(ALLO)
undefined
undefined%
At close: undefined
1.94
2.92%
After-hours Dec 13, 2024, 06:59 PM EST
Cashflow (Annual)
Get detailed ratio statement breakdowns, uncovering price to
free cash flow ratio, price per earnings, and much more.
| Year | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 |
| Net Income | -327.26M | -332.63M | -257.00M | -250.22M | -184.59M | -211.50M | -24.00K |
| Depreciation & Amortization | 14.20M | 14.29M | 10.45M | 7.59M | 5.03M | 1.50M | - |
| Stock-Based Compensation | 65.95M | 83.60M | 80.82M | 65.26M | 46.06M | 18.57M | - |
| Other Working Capital | -7.80M | -1.16M | -31.32M | 53.31M | -5.89M | 3.30M | 24.00K |
| Other Non-Cash Items | 24.69M | 2.43M | 2.61M | 3.96M | 3.36M | 134.81M | - |
| Deferred Income Tax | - | 8.08M | 10.40M | 4.40M | -331.00K | -117.00K | - |
| Change in Working Capital | -15.30M | 3.71M | -32.09M | 53.92M | -6.88M | 12.10M | 24.00K |
| Operating Cash Flow | -237.73M | -220.52M | -184.81M | -115.09M | -137.35M | -44.65M | - |
| Capital Expenditures | -1.52M | -5.19M | -21.45M | -65.96M | -50.79M | -3.23M | - |
| Acquisitions | - | -111.35M | -17.71M | 439.17M | -5.08M | - | - |
| Purchase of Investments | -438.63M | -248.11M | -525.58M | -1.04B | -252.63M | -649.31M | - |
| Sales Maturities Of Investments | 603.43M | 359.46M | 728.39M | 598.43M | 472.58M | 21.84M | - |
| Other Investing Acitivies | - | 111.35M | 185.10M | -439.17M | 214.88M | -2.10M | - |
| Investing Cash Flow | 163.29M | 106.16M | 163.66M | -505.12M | 164.08M | -632.80M | - |
| Debt Repayment | - | - | - | - | - | 116.84M | - |
| Common Stock Repurchased | - | 2.46M | 3.62M | - | - | - | - |
| Dividend Paid | - | - | - | - | - | - | - |
| Other Financial Acitivies | 4.58M | 2.95M | 11.96M | 11.66M | 4.74M | 953.62M | - |
| Financial Cash Flow | 95.69M | 2.95M | 11.96M | 633.59M | 58.96M | 771.18M | - |
| Net Cash Flow | 21.25M | -111.41M | -9.19M | 13.38M | 85.69M | 93.73M | - |
| Free Cash Flow | -239.25M | -225.71M | -206.26M | -181.05M | -188.14M | -47.89M | - |